Los Angeles – Nov 9, 2023
Terray Therapeutics, a biotechnology company pioneering AI-driven small molecule discovery, has secured an equity investment from NVentures, NVIDIA’s venture capital arm. This financing, bolstered by leading institutional investors and industry veterans such as John Maraganore (founding CEO of Alnylam Pharmaceuticals) and Bassil Dahiyat (CEO of Xencor), positions Terray at the forefront of AI-enabled drug design.
Accelerating AI-Driven Chemistry with NVIDIA’s Cutting-Edge Technology
Through this collaboration, Terray will harness NVIDIA DGX™ Cloud to develop the world’s most advanced chemistry foundation models for small molecule drug discovery. Select models will also be made available through NVIDIA BioNeMo™, a generative AI cloud platform for drug design. By integrating NVIDIA’s full-stack AI computing expertise, Terray aims to scale its generative AI models, optimizing small molecule design with unprecedented speed and accuracy.
“We believe the scale, precision, and quality of our experimental data uniquely position us to harness the power of NVIDIA technologies,” said Jacob Berlin, Ph.D., CEO of Terray Therapeutics. “With NVIDIA’s AI-driven infrastructure, we can efficiently explore vast molecular space and solve complex challenges in drug discovery.”
Generative AI’s Transformational Role in Biopharma
The integration of Terray’s massive, high-resolution experimental datasets with NVIDIA’s AI infrastructure will enable next-generation ligand- and structure-based models, accelerating both internal and partnered drug development pipelines.
“Generative AI is making an outsized impact on the biotech industry,” said Mohamed “Sid” Siddeek, corporate vice president and head of NVentures. “Terray’s innovative approach to training AI foundation models on NVIDIA’s accelerated computing platform will drive important breakthroughs in drug discovery.”
Redefining Drug Discovery with Scalable AI Innovation
Terray’s platform uniquely integrates ultra-high throughput experimentation, generative AI, and advanced computation to improve the success rate of small molecule drug development. By continuously generating precise, purpose-built data, Terray enhances molecular profiling, fueling iterative AI-driven design cycles that improve predictive accuracy.
With NVIDIA’s support, Terray is poised to revolutionize the biopharma landscape, unlocking new possibilities for AI-powered small molecule therapeutics that could significantly accelerate drug discovery and development.
About Terray Therapeutics
Terray Therapeutics is a biotechnology company pioneering a data-driven approach to small-molecule drug discovery. By integrating ultra-high throughput experimentation, generative AI, medicinal chemistry, and nanotechnology, Terray’s platform enables rapid and efficient identification of promising drug candidates. The company’s tNova platform blends large-scale proprietary experimental data with AI-driven insights to advance the next generation of precision therapeutics.
More about news
By